BACKGROUND: Mindfulness-based stress reduction (MBSR) programs have consistently been shown to enhance the psychosocial well-being of participants. Given the well-established association between psychosocial factors and immunologic functioning, it has been hypothesized that enhanced psychosocial well-being among MBSR participants would be associated with corresponding changes in markers of immune activity. OBJECTIVES: The objectives of this study were to examine changes in psychosocial and immunologic measures in a heterogeneous patient sample following participation in a MBSR program. DESIGN: A single-group, pretest/post-test design was utilized. SETTING: The intervention was conducted at an academic health center. SUBJECTS: This pilot study involved 24 participants (aged 28-72 years). Inclusion criteria were as follows: > or =18 years of age, English-speaking, and no known autoimmune disorder. INTERVENTION: The intervention was an 8-week MBSR program. OUTCOME MEASURES: Distress and quality of life (QOL) measures included the Brief Symptom Inventory-18 and the Medical Outcomes Survey Short-Form Health Survey, respectively. Immunologic measures included natural killer (NK) cell cytolytic activity and C-reactive protein (CRP). RESULTS: Patients completed psychosocial assessments and provided a blood sample at baseline (pre-MBSR) and within 2 weeks post-MBSR. Significant improvements in anxiety and overall distress as well as across multiple domains of QOL were observed from baseline to post-MBSR. Reductions in anxiety and overall distress were associated with reductions in CRP. Patients who reported improvement in overall mental well-being also showed increased NK cytolytic activity from pre- to post-MBSR, whereas patients who reported no improvement in mental well-being showed no change in NK cytolytic activity. CONCLUSIONS: Positive improvement in psychologic well-being following MBSR was associated with increased NK cytolytic activity and decreased levels of CRP.
BACKGROUND: Mindfulness-based stress reduction (MBSR) programs have consistently been shown to enhance the psychosocial well-being of participants. Given the well-established association between psychosocial factors and immunologic functioning, it has been hypothesized that enhanced psychosocial well-being among MBSR participants would be associated with corresponding changes in markers of immune activity. OBJECTIVES: The objectives of this study were to examine changes in psychosocial and immunologic measures in a heterogeneous patient sample following participation in a MBSR program. DESIGN: A single-group, pretest/post-test design was utilized. SETTING: The intervention was conducted at an academic health center. SUBJECTS: This pilot study involved 24 participants (aged 28-72 years). Inclusion criteria were as follows: > or =18 years of age, English-speaking, and no known autoimmune disorder. INTERVENTION: The intervention was an 8-week MBSR program. OUTCOME MEASURES: Distress and quality of life (QOL) measures included the Brief Symptom Inventory-18 and the Medical Outcomes Survey Short-Form Health Survey, respectively. Immunologic measures included natural killer (NK) cell cytolytic activity and C-reactive protein (CRP). RESULTS:Patients completed psychosocial assessments and provided a blood sample at baseline (pre-MBSR) and within 2 weeks post-MBSR. Significant improvements in anxiety and overall distress as well as across multiple domains of QOL were observed from baseline to post-MBSR. Reductions in anxiety and overall distress were associated with reductions in CRP. Patients who reported improvement in overall mental well-being also showed increased NK cytolytic activity from pre- to post-MBSR, whereas patients who reported no improvement in mental well-being showed no change in NK cytolytic activity. CONCLUSIONS: Positive improvement in psychologic well-being following MBSR was associated with increased NK cytolytic activity and decreased levels of CRP.
Authors: Marcus Majumdar; Paul Grossman; Barbara Dietz-Waschkowski; Susanne Kersig; Harald Walach Journal: J Altern Complement Med Date: 2002-12 Impact factor: 2.579
Authors: Steven D Douglas; Margaret Camarca; Jiahong Xu; Stephen Durako; Debra Murphy; Barbara Moscicki; Craig M Wilson Journal: AIDS Res Hum Retroviruses Date: 2003-05 Impact factor: 2.205
Authors: Autumn M Gallegos; Michael Hoerger; Nancy L Talbot; Michael S Krasner; Jennifer M Knight; Jan A Moynihan; Paul R Duberstein Journal: J Altern Complement Med Date: 2013-02-05 Impact factor: 2.579
Authors: Aleezé S Moss; Diane K Reibel; Jeffrey M Greeson; Anjali Thapar; Rebecca Bubb; Jacqueline Salmon; Andrew B Newberg Journal: J Appl Gerontol Date: 2014-12-09